• ALC-0159 for mRNA Lipid Nanoparticle Workflows

  2026-09-30

  ALC-0159 is a PEG-conjugated lipid excipient for building and refining mRNA lipid nanoparticles, including formulations used in cancer-immunotherapy research. This practical guide separates formulation variables from biological effects and provides executable starting conditions, assay choices, and troubleshooting checkpoints.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit Guide

  2026-09-30

  Build bright, sequence-specific RNA probes for in situ hybridization, Northern blot hybridization, and RNA–protein condensation studies with tunable Cy5-UTP incorporation. This workflow-focused guide connects the HyperScribe kit to practical assay design while separating product capabilities from findings reported in SARS-CoV-2 nucleocapsid research.

• ALOX5 and Ferroptosis in CRSwNP Barrier Dysfunction

  2026-09-29

  Huang et al. integrate endoplasmic-reticulum-stress gene analysis, co-expression networks, machine learning, single-cell transcriptomics, and experimental validation to prioritize ALOX5 as a ferroptosis-associated candidate in chronic rhinosinusitis with nasal polyps. The study links ALOX5 expression with disease severity and epithelial tight-junction changes, while also defining a practical framework for validating low-abundance proteins in nasal tissue and epithelial-cell models.

• Mildronate Lipidoids for Lower-Inflammation mRNA Delivery

  2026-09-29

  The ACS Nano study developed mildronate-derived cationic lipids and a low-lipid nanoparticle formulation, mLNP-69, to preserve mRNA delivery while reducing local inflammatory effects. In prophylactic and therapeutic B16OVA melanoma models, the formulation supported effective mRNA cancer vaccination, providing a useful framework for delivery-aware vaccine development research.

• CTOP and the Circuit Logic of Opioid Pain

  2026-09-28

  CTOP is a selective μ-opioid receptor antagonist for resolving how receptor activation contributes to opioid-induced mechanical hypersensitivity and tolerance. This article translates recent brain-to-spinal circuit findings into practical assay and interpretation strategies.

• Angiotensin II at the Exposure–Vascular Interface

  2026-09-28

  A 2026 study connects bisphenol A exposure with abdominal aortic aneurysm biology through inflammation, extracellular-matrix disruption, smooth-muscle phenotype changes, and senescence. This article considers how Angiotensin II can serve as a distinct, controlled vascular perturbation—not a presumed mediator of BPA toxicity—to help translational researchers separate exposure-related effects from receptor-driven cardiovascular remodeling.

• Cy5 RNA Labeling Kit: From Signal to Assay Design

  2026-09-27

  The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit supports flexible fluorescent RNA probe synthesis for hybridization assays. This guide explains how to balance labeling with transcript production—and why a fluorescent probe answers a different question from therapeutic mRNA delivery.

• Vincristine Sulfate: From Mechanism to Translation

  2026-09-26

  A translational framework for using vincristine sulfate to connect tubulin engagement with reproducible cancer research outcomes—while keeping model-specific evidence and broader hypotheses in their proper context.

• Putting Mammalian Embryonic Cells into Dormancy

  2026-09-25

  A Nature Protocols paper describes reversible, in vitro induction of a diapause-like state in mouse blastocysts, human blastoids and mouse or human pluripotent stem cells using pharmacological mTOR inhibition. The workflow provides a scalable alternative to invasive in vivo models for studying embryonic dormancy, while emphasizing that dormancy must be assessed through both state maintenance and the capacity to resume development.

• LY-411575: Potent Gamma-Secretase Inhibitor

  2026-09-25

  LY-411575 is a potent gamma-secretase inhibitor used to study amyloid beta production and Notch signaling pathway inhibition. Product information reports subnanomolar activity in membrane-based and cell-based assays, while a 2024 TNBC study supplies a separate rationale for investigating Notch inhibition in cancer research—not proof that LY-411575 itself improves cancer treatment.

• EZ Cap™ Cy5 EGFP mRNA for LNP Assays

  2026-09-24

  Use a single dual-fluorescence reporter to separate mRNA uptake from downstream EGFP expression when comparing delivery formulations. This practical guide shows how to pilot the reporter in nanoparticle workflows, interpret its signals, and troubleshoot common assay gaps without treating fluorescence as proof of intact RNA or therapeutic performance.

• 10058-F4: c-Myc-Max Inhibition in Practice

  2026-09-24

  Use 10058-F4 to test how disrupting c-Myc:MAX affects transcription, cell fate, and apoptosis—with distinct workflows for cancer models and TERT-focused stem-cell research. Practical dose-finding, formulation, and troubleshooting guidance helps separate target-linked effects from vehicle or general toxicity.

• Angiotensin 1/2 (5-7): Designing Better Binding Assays

  2026-09-23

  Angiotensin 1/2 (5-7) is a compact H2N-Ile-His-Pro-OH peptide with emerging relevance to receptor-resolved SARS-CoV-2 spike binding studies. This guide interprets the evidence, clarifies what binding assays can establish, and outlines practical choices for rigorous peptide experiments.

• Angiotensin 1/2 (5-7): From RAS to Translation

  2026-09-23

  Angiotensin 1/2 (5-7) is more than a short renin-angiotensin system fragment: it is a defined molecular probe for connecting peptide sequence, cardiovascular signaling, and emerging spike-protein binding biology. This article examines its mechanistic rationale, assay strategy, translational value, and limitations for researchers designing reproducible hypertension and cross-domain studies.

• MMV Pandemic Response Box: Antimicrobial Screening Findings

  2026-09-22

  This study systematically screened compounds from the MMV Pandemic Response Box against multidrug-resistant bacterial and clinically relevant fungal isolates, combining MIC testing with a bacterial persister assay. Its findings prioritize epetraborole, eravacycline, MMV compounds, and several antifungal agents for follow-up while illustrating how early phenotypic screening can distinguish growth inhibition from fungicidal or bactericidal activity.

7871 records 1/525 page Next 12345 下5页 Last page